Two CBC Pioneers at the core of Tempus
Tempus, a new Chicago-based health technology company focused on personalized cancer care, has recently announced its first partnership with Northwestern University’s Lurie Comprehensive Cancer Center. The premise of the collaboration is to enable the physicians to develop data-based, patient-specific cancer therapies by providing real-time access to a constantly growing genomic cancer database.
Tempus, officially launched in Chicago in October 2016, was co-founded by the Groupon co-founder Eric Lefkofsky. Two CBC affiliates hold prominent positions at Tempus: Kevin White and Jonathan Silverstein. White, who serves as President at Tempus, received the first CBC Recruitment Award in 2006, and is the founding Director of the Institute for Genomics and Systems Biology (IGSB) at The University of Chicago. Silverstein serves as Tempus’s Chief Medical Informatics Officer and was one of the founding scientific directors of the Chicago Biomedical Consortium.
The CBC is excited that Silverstein and White are “…forging new ground by building a biotech center of gravity in Chicago,” in the words of White.
Tempus’s momentum is indeed rapidly growing. The company has already created close to 100 new jobs in Chicago. On Oct. 4, 2016, Tempus announced that it was selected by the Pancreatic Cancer Action Network to serve as a partner in its Precision Promise initiative, the first large-scale precision medicine trial designed to transform outcomes for patients with pancreatic cancer. A CBC member school, The University of Chicago, is one of the 12 initial Clinical Trial Consortium sites participating in Precision Promise.
Only a week later, on Oct. 11, Tempus entered another partnership with the University of Michigan Comprehensive Cancer Center to bring MI-ONCOSEQ to patients and health care providers across the country who are seeking the high quality data and analyses necessary to personalize treatment for their patients.
The CBC is very proud to see its collaborative spirit bridge the new efforts in Chicago and beyond, fulfilling its mission to “Transform research at the frontiers of biomedicine” and to “Promote the development of the biomedical industry in Chicago.”
▸ Tempus website
▸ Tempus and Northwestern’s Lurie Cancer Center Announce Personalized Medicine Partnership For Cancer Patients
▸ Lefkofsky Startup Takes on Cancer
▸ Tempus Selected by Pancreatic Cancer Action Network as Partner for New Personalized Medicine Initiative
▸ Tempus And University Of Michigan Announce Personalized Medicine Partnership For Cancer Patients